Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline

Johnson & Johnson (JNJ) shares are trading higher following significant biotech acquisitions aimed at expanding its oncology pipeline. The company is acquiring Firefly Bio Inc. for $1 billion and has partnered with Sail Biomedicines, with an option to buy it for $2.58 billion, to target hard-to-treat solid tumors. Despite potential short-term EPS dilution from these deals, J&J's stock shows a bullish long-term bias supported by strong technical indicators and recent settlement of talc cases, allowing focus on pipeline execution.